Latest news with #MMJ
Yahoo
2 days ago
- Business
- Yahoo
President Trump's Marijuana Fix? DEA's Program Exposed: Promises Made, Promises Not Kept
"As President Trump weighs marijuana rescheduling in the coming weeks, the DEA's track record reveals years of mismanagement, empty promises, and patients left waiting," stated MMJ CEO Duane Boise. WASHINGTON, D.C. / / August 17, 2025 / President Trump's decision to potentially reschedule marijuana is the first serious step in decades to break through the bureaucratic logjam that has kept patients and scientists waiting. For years, the DEA has promised a functional marijuana research program. For years, those promises have been broken. DEA's Promises on Paper In its Final Rule (85 Fed. Reg. 82333, Dec. 18, 2020), the DEA pledged that marijuana manufacturing licenses would be tied to FDA science and genuine medical research. The agency declared: "DEA will evaluate each application… to determine whether the applicant's proposed activities… will promote medical research." "DEA will require applicants to demonstrate bona fide supply agreements with researchers authorized by the FDA to conduct clinical research." "DEA's goal is to ensure that the United States has a sufficient supply of marihuana to meet the legitimate medical, scientific, and research needs of the United States." These were the promises. The Harsh Reality But DEA's actions told a different story: Licenses granted to companies with no FDA INDs, no clinical trial protocols, and no scientific foundation. No bona fide supply agreements with FDA-authorized researchers - a direct violation of DEA's own Final Rule. Four years later, there is still no adequate, federally compliant supply of cannabis for clinical trials, leaving patients with Huntington's Disease, Multiple Sclerosis, and other conditions waiting. The only company that meets DEA's own published criteria - MMJ BioPharma, with two FDA-filed INDs and an Orphan Drug Designation - has been stalled while non-scientific registrants received licenses. Promises Made, Promises Not Kept DEA's marijuana program has been a case study in mismanagement: Rules written, then ignored. Patients promised access, then denied it. Science promised priority, then sidelined. President Trump's possible rescheduling decision shines a spotlight on this failure. By moving marijuana to Schedule III, he has forced the issue back into the open and made clear that real reform will require DEA accountability. The Path Forward Patients deserve more than empty promises. They deserve consistent, reproducible, FDA-approved medicines. They deserve agencies that follow their own rules. And they deserve leadership that keeps its word. With rescheduling now on the table, it is time to hold DEA to account for the gap between its promises and its performance. President Trump has taken the first step - now the DEA must be compelled to deliver. MMJ is represented by attorney Megan Sheehan. CONTACT:Madison HiseyMHisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire
Associated Press
2 days ago
- Business
- Associated Press
President Trump's Marijuana Fix? DEA's Program Exposed: Promises Made, Promises Not Kept
' As President Trump weighs marijuana rescheduling in the coming weeks, the DEA's track record reveals years of mismanagement, empty promises, and patients left waiting,' stated MMJ CEO Duane Boise. WASHINGTON, D.C. / ACCESS Newswire / August 17, 2025 / President Trump's decision to potentially reschedule marijuana is the first serious step in decades to break through the bureaucratic logjam that has kept patients and scientists waiting. For years, the DEA has promised a functional marijuana research program. For years, those promises have been broken. DEA's Promises on Paper In its Final Rule (85 Fed. Reg. 82333, Dec. 18, 2020), the DEA pledged that marijuana manufacturing licenses would be tied to FDA science and genuine medical research. The agency declared: These were the promises. The Harsh Reality But DEA's actions told a different story: The only company that meets DEA's own published criteria - MMJ BioPharma, with two FDA-filed INDs and an Orphan Drug Designation - has been stalled while non-scientific registrants received licenses. Promises Made, Promises Not Kept DEA's marijuana program has been a case study in mismanagement: President Trump's possible rescheduling decision shines a spotlight on this failure. By moving marijuana to Schedule III, he has forced the issue back into the open and made clear that real reform will require DEA accountability. The Path Forward Patients deserve more than empty promises. They deserve consistent, reproducible, FDA-approved medicines. They deserve agencies that follow their own rules. And they deserve leadership that keeps its word. With rescheduling now on the table, it is time to hold DEA to account for the gap between its promises and its performance. President Trump has taken the first step - now the DEA must be compelled to deliver. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
Associated Press
07-08-2025
- Health
- Associated Press
Massachusetts Cannabis Contamination Crisis Exposes Federal Negligence While DEA Targets Science, Not Safety
Where Is the DEA? The Real Threat Isn't Research-It's Rotten Weed. 'This is the height of hypocrisy, " said Duane Boise, CEO MMJ. " DEA bureaucrats are blocking clean cannabis grown in a DEA inspected cultivation facility, while contaminated products circulate freely under their watch. The agency has abandoned its duty to protect patients.' WASHINGTON, DC / ACCESS Newswire / August 7, 2025 / While the Massachusetts Cannabis Control Commission scrambles to contain a major public health scandal involving 544 contaminated marijuana samples, Thomas Prevoznik and the Drug Enforcement Administration (DEA)-the agency that claims to 'protect public health and safety from the dangers of drugs"-is nowhere to be found. According to a Public Health and Safety Advisory issued today by the Massachusetts Commission, contaminated and potentially contaminated marijuana products were sold throughout the state between April 1, 2024, and April 15, 2025. The issue? The products failed Total Yeast and Mold testing -a serious risk to patients and consumers, especially those who are immunocompromised. Yet this failure of regulatory oversight occurred right under DEA's nose, in a federally illegal marketplace they claim to police. So, we ask again: Where is the DEA? Moldy Marijuana, Real Harm Massachusetts authorities have confirmed that hundreds of samples tested positive for contaminants but were somehow allowed to enter commercial circulation. This isn't about labeling violations or clerical errors-it's about inhaled mold, a known trigger for respiratory infections, allergic reactions, and even long-term lung damage. The contaminated products were tracked using Metrc, a seed-to-sale traceability system required by law. The system worked. But what failed? Federal oversight, accountability, and DEA enforcement. DEA Targets Science, Not Safety While moldy weed was being sold to unsuspecting patients, what was the DEA doing? Let's be clear: the DEA is not protecting public health. It's obstructing it. The Real Threat Isn't Research-It's Rotten Weed The DEA's warped priorities are now a matter of public danger. Instead of helping to build a controlled, pharmaceutical-grade cannabis pipeline, the agency enables a fragmented, state-by-state chaos where contaminated products slip through the cracks and patients pay the price. Ironically, the same agency that refuses to allow MMJ to grow clean, pharmaceutical cannabis in a DEA inspected facility also looks the other way as moldy, hazardous marijuana circulates in retail dispensaries. MMJ BioPharma: Compliant, Blocked, and Ignored MMJ BioPharma has: And yet- after seven years -no federal approval. A Simple Question for Administrator Terry Cole Now that the Senate has confirmed Terry Cole as DEA Administrator, the public deserves an answer: Will you keep blocking clean, FDA-regulated cannabis research while patients unknowingly inhale moldy weed from state markets you refuse to regulate? The answer to that question will define not only your legacy-but whether the DEA finally chooses science over sabotage. Final Thoughts The DEA says it exists to fight drug abuse and protect public health. But in the face of real harm- contaminated marijuana entering legal markets -it's missing in action. It's time for a new era of leadership. One where medical science leads, and moldy lies die. The time for excuses is over. The time for action is now. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-85832 SOURCE: MMJ International Holdings press release
Associated Press
30-07-2025
- Business
- Associated Press
DEA's Marijuana Hypocrisy Laid Bare: As Rescheduling Looms, Agency's Ethical Failures and Research Obstruction Spark Outrage
Terrance Cole's First Test as Administrator MMJ BioPharma Cultivation 's case exposes DEA's Diversion Control Division as a cartel of obstructionists who have abandoned science, betrayed public trust, and refused to follow the law. New DEA Administrator Terrance Cole inherited a mess. But now he has a chance to do something Judge Mulrooney, Thomas Prevoznik, Matthew Strait and Aarathi Haig never would: Tell the truth. Follow the law. And approve MMJ's long-blocked registration so clinical trials can finally begin. WASHINGTON, DC / ACCESS Newswire / July 30, 2025 / While the Drug Enforcement Administration (DEA) teases potential marijuana rescheduling, its actions reveal a disturbing pattern of hypocrisy: blocking federally compliant medical research while turning a blind eye to illegal corporate exports and harboring attorneys who flout ethical standards. For companies like MMJ BioPharma Cultivation-which has meticulously followed federal law for seven years-the DEA's conduct suggests not bureaucratic inertia, but deliberate sabotage of scientific progress, underscored by ethical breaches within its own ranks. The Haig Scandal: A DEA Attorney Operating Without Legal Standing At the center of the storm is DEA attorney Aarathi Haig, who continues to lead high-profile cases, including the agency's fight against MMJ BioPharma Cultivation, despite being ineligible for a Certificate of Good Standing with the New Jersey Bar. Records show Haig: Federal law (28 U.S.C. § 530B) mandates that government attorneys comply with state bar rules, yet the DEA has taken no apparent action against Haig. 'This isn't about paperwork-it's about a pattern of disregard for the law,' said Duane Boise, CEO of MMJ BioPharma. 'The DEA demands compliance from others while ignoring its own obligations' . MMJ BioPharma Cultivation's Ordeal: A Case Study in DEA Corrupt Obstruction MMJ BioPharma's struggle exposes the DEA's double standard: Meanwhile, the DEA ignores recreational cannabis companies illegally exporting THC products to Europe while stonewalling MMJ's compliant research. The Bigger Picture: A System Rigged Against Science The DEA's own Diversion Control Manual (Sections 5202.5, 5201.12) mandates support for 'bona fide Schedule I research' and expedited approvals-policies Prevoznik and Haig have blatantly ignored. The agency's actions reveal: A Call for Accountability With incoming DEA Administrator Terrance Cole poised to take office, advocates demand: 'The DEA administrative hearing system is a constitutional dead man walking,' Boise declared. 'Every day it clings to this broken system, it digs its grave deeper' The public deserves answers. The patients deserve justice. The time for DEA accountability is now. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
Yahoo
11-06-2025
- Health
- Yahoo
NuggMD Now Serves All Eligible Medical Cannabis Patients Nationwide via Secure Telehealth Platform
Trusted Telemedicine Platform for Medical Marijuana Expands Access Across 25+ States Where Legal Los Angeles, June 10, 2025 (GLOBE NEWSWIRE) -- NuggMD, the nation's leading medical marijuana telehealth platform, is proud to announce that it now provides secure access to medical cannabis evaluations in every state where telemedicine is legally permitted for medical marijuana recommendations. This milestone solidifies NuggMD's position as the most accessible and trusted telehealth solution for patients seeking legal, medical cannabis care across the United States. The expansion comes at a time when patients nationwide are seeking alternative wellness solutions, and state regulations are increasingly embracing the role of telemedicine in expanding healthcare access. NuggMD now serves patients in over 25 states, offering HIPAA-compliant virtual consultations with licensed medical professionals 7 days a week. 'Millions of Americans still face unnecessary barriers to medical cannabis access,' said a spokesperson for NuggMD. 'With our national expansion, we're helping to break down those barriers by delivering fast, safe, and fully compliant telehealth services to qualified patients no matter where they live.' Serving Over 1 Million Patients – With Compassion and Convenience Since its launch in 2016, NuggMD has facilitated over 1 million medical cannabis evaluations, making it the most widely used and patient-trusted telemedicine platform in the space. By providing instant access to state-licensed healthcare providers, NuggMD eliminates the delays, confusion, and cost burdens often associated with in-person clinics. Through NuggMD, patients can: Speak directly with a licensed practitioner via secure video call Get approved in minutes, often within 15–20 minutes of booking Receive instant digital documentation (where permitted by law) Access clear guidance on how to register with their state's MMJ program Experience 100% risk-free evaluations – no charge if not approved Pioneering the Future of Telemedicine in Medical Cannabis As healthcare continues to evolve toward digital-first models, NuggMD remains at the forefront of legal telehealth services for alternative treatments. The company works directly with certified doctors and state regulators to ensure every evaluation meets strict privacy and medical standards. 'We're committed to making medical cannabis more accessible, especially for patients with chronic pain, anxiety, PTSD, and other qualifying conditions,' said a company representative. 'Our platform is built around compassion, security, and compliance.' For a complete list of eligible states and to schedule a consultation, visit: About NuggMDNuggMD is the nation's leading telemedicine platform for medical cannabis evaluations, trusted by over 1 million patients since 2016. With a mission to improve access to alternative wellness care, NuggMD offers safe, secure, and state-compliant evaluations from licensed healthcare professionals across the United States. Contact:NuggMDsupport@ (866) 847-7205https:// Source: NuggMD Legal Disclaimer: This news release is for informational purposes only and does not constitute medical or legal advice. Services are available only in states that allow telehealth for medical cannabis evaluations. Patients must meet eligibility requirements set forth by their respective state programs. Always consult a licensed healthcare provider before beginning any treatment plan. CONTACT: support@ Phone: (866) 847-7205Sign in to access your portfolio
